Kura Oncology (NASDAQ:KURA) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating

Kura Oncology (NASDAQ:KURA) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

KURA has been the subject of a number of other reports. Jefferies Financial Group cut their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Bank of America dropped their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, JMP Securities restated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Stock Performance

KURA opened at $7.33 on Tuesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $8.10 and its 200 day moving average price is $13.64. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The firm has a market capitalization of $570.01 million, a PE ratio of -3.11 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. As a group, sell-side analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in KURA. Virtus ETF Advisers LLC increased its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Harbor Advisors LLC purchased a new position in shares of Kura Oncology during the fourth quarter worth about $87,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology in the 4th quarter valued at about $90,000. Corton Capital Inc. purchased a new stake in Kura Oncology during the 4th quarter valued at approximately $99,000. Finally, Optimize Financial Inc acquired a new stake in Kura Oncology during the 4th quarter worth approximately $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.